These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28694672)

  • 41. [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
    Tanida T; Tanemura M; Kobayashi S; Wada H; Marubashi S; Eguchi H; Takeda Y; Umeshita H; Mori M; Doki Y; Nagano H
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2729-31. PubMed ID: 21224694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
    Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
    Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
    Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
    Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
    Front Immunol; 2022; 13():943066. PubMed ID: 36159865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population.
    Zhao XQ; Ma HX; Su MS; He L
    Int J Clin Exp Pathol; 2014; 7(10):6914-21. PubMed ID: 25400775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
    Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
    Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proximal biliary tumors.
    Brown KM; Geller DA
    Surg Clin North Am; 2014 Apr; 94(2):311-23. PubMed ID: 24679423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary or metastatic hepatic carcinoma? A breast cancer patient after adjuvant chemotherapy and radiotherapy postoperatively with intrahepatic cholangiocarcinoma and review of the literature.
    Liu ZY; Sun JJ; He KW; Zhuo PY; Yu ZY
    World J Surg Oncol; 2016 Jul; 14(1):183. PubMed ID: 27422708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.
    Wei M; Lü L; Lin P; Chen Z; Quan Z; Tang Z
    Cancer Lett; 2016 Sep; 379(2):253-61. PubMed ID: 26940139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.
    Yamashita Y; Ishii Y; Serikawa M; Okamoto W; Tsuboi T; Tatsukawa Y; Nakamura S; Hirano T; Ikemoto J; Oka S
    Clin J Gastroenterol; 2023 Jun; 16(3):470-475. PubMed ID: 36806982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
    Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
    Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
    Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
    Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of clinicopathological characteristics between patients with occupational and non-occupational intrahepatic cholangiocarcinoma.
    Hamano G; Kubo S; Takemura S; Tanaka S; Shinkawa H; Kinoshita M; Ito T; Yamamoto T; Wakasa K; Shibata T
    J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):389-96. PubMed ID: 27062258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Tsunematsu S; Chuma M; Kamiyama T; Miyamoto N; Yabusaki S; Hatanaka K; Mitsuhashi T; Kamachi H; Yokoo H; Kakisaka T; Tsuruga Y; Orimo T; Wakayama K; Ito J; Sato F; Terashita K; Nakai M; Tsukuda Y; Sho T; Suda G; Morikawa K; Natsuizaka M; Nakanishi M; Ogawa K; Taketomi A; Matsuno Y; Sakamoto N
    Abdom Imaging; 2015 Aug; 40(6):1492-9. PubMed ID: 25579172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imaging of intrahepatic and hilar cholangiocarcinoma.
    Choi BI; Lee JM; Han JK
    Abdom Imaging; 2004; 29(5):548-57. PubMed ID: 15185025
    [No Abstract]   [Full Text] [Related]  

  • 58. A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM-STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma.
    Chen ZW; Kang FP; Xie CK; Liao CY; Li G; Wu YD; Lin HY; Zhu SC; Hu JF; Lin CF; Huang Y; Tian YF; Huang L; Wang ZW; Chen S
    Adv Sci (Weinh); 2023 Nov; 10(32):e2303814. PubMed ID: 37789644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
    Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
    Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnosis of cholangiocarcinoma: a case series and literature review.
    Jabara B; Fargen KM; Beech S; Slakey DR
    J La State Med Soc; 2009; 161(2):89-94. PubMed ID: 19489389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.